Longitudinal study on lung cancer using proteomics analysis
LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics
This study is trying to see if analyzing proteins in blood and tissue samples from lung cancer patients can help doctors better understand the disease and improve treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06778512 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a longitudinal cohort for proteomics analysis in lung cancer patients by utilizing tissue and peripheral blood samples. It will focus on key treatment time points, including screening, postoperative efficacy prediction, and evaluation of therapeutic outcomes. The goal is to explore the potential of proteomics in distinguishing between benign and malignant lung conditions and assessing long-term prognosis. By analyzing protein profiles, the study seeks to enhance the understanding of lung cancer diagnosis and treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with lung nodules confirmed by CT examination and good preoperative pulmonary function.
Not a fit: Patients with severe respiratory disorders or significant imaging artefacts may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of lung cancer diagnosis and treatment efficacy predictions for patients.
How similar studies have performed: While proteomics has been explored in other cancer studies, this specific longitudinal approach in lung cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signing of the informed consent form; 2. Male or female, aged 18-75 years; 3. Patients with lung nodules confirmed by CT examination; 4. Good preoperative pulmonary function cooperation and complete reporting; 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging; 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month. Exclusion Criteria: 1. Poor preoperative pulmonary function cooperation or missing reports; 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission; 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month; 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.); 5. Coexisting with other severe functional impairments; 6. Patients with obstructive lesions such as airway or esophageal stenosis; (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Where this trial is running
Guangzhou, Guangdong
- the First Affiliated of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jianxing He, Professor
- Email: drjiaxing.he@gmail.com
- Phone: 86-20-83337792
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.